SCHEMBL30677249

SCHEMBL30677249

COc1cccc(-n2c(C)nc3c(NN)nc(Cl)nc32)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.47
▸ YTHDC1 Q96MU7 1/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ TSHR P16473 2/20 0.43
▸ HTT P42858 2/20 0.43
▸ FYN P06241 1/20 0.41
▸ EPHB4 P54760 1/20 0.41
▸ CRHR1 P34998 3/20 0.41
▸ THRB P10828 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ LMNA P02545 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.38
▸ USP2 O75604 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ GLA P06280 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ CASP1 P29466 1/20 0.38
▸ CASP7 P55210 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30677266 0.84 CYP1A2 (0.52) CYP1A2YTHDC1SMN1; SMN2TSHRHTT
SCHEMBL30677410 0.84 PI4KA (0.48) YTHDC1TSHRHTTCRHR1USP2
SCHEMBL31576372 0.79 GSK3B (0.45) SMN1; SMN2THRBMAPTLMNAKDM4E
SCHEMBL30677385 0.79 GSK3B (0.45) SMN1; SMN2THRBMAPTLMNAKDM4E
SCHEMBL30677424 0.72 CCNA2 (0.40) YTHDC1SMN1; SMN2MAPTALDH1A1
SCHEMBL1272301 0.71 NR1H2 (0.65) CYP1A2SMN1; SMN2TSHRHTTTHRB
SCHEMBL30677485 0.66 PI4KA (0.50) TSHRHTTCRHR1USP2ALDH1A1
SCHEMBL31576405 0.65 MAPT (0.47) CYP1A2SMN1; SMN2HTTMAPTLMNA
SCHEMBL1271040 0.64 NR1H2 (0.67) CYP1A2SMN1; SMN2THRBNR1H2NR1H3
SCHEMBL30677377 0.64 XDH (0.57) YTHDC1TSHRHTTLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388582-A1 NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF ILDONG PHARMACEUTICAL CO LTD (KR) 2025-12-25 — — US disclosed
EP-4556476-A1 NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF Ildong Pharmaceutical Co., Ltd. (KR) 2025-05-21 — — EP disclosed
WO-2024014885-A1 NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF 일동제약(주) 2024-01-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388582-A1 NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF GBA1, PIKFYVE, MAN2B1 CYP1A2 3958/4885YTHDC1 3248/4885SMN1; SMN2 835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback